Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCX NYSE:INFU NYSE:ISR NYSE:NSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$2.43-4.7%$2.95$0.17▼$1.27$50.80M0.514.65 million shs24,659 shsINFUInfuSystem$10.42+1.6%$7.70$4.61▼$11.04$212.84M1.82179,389 shs316,773 shsISRIsoray$0.37$0.19▼$0.45$54.57M1.48290,697 shs145,000 shsNSPRInspireMD$2.46+2.5%$2.43$1.99▼$3.80$102.63M0.68101,203 shs52,707 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell0.00%-4.32%-10.00%-5.08%+415.27%INFUInfuSystem+0.98%-4.82%+16.19%+69.59%+75.68%ISRIsoray0.00%0.00%0.00%0.00%0.00%NSPRInspireMD-0.83%-1.64%-0.83%-1.64%-14.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$2.43-4.7%$2.95$0.17▼$1.27$50.80M0.514.65 million shs24,659 shsINFUInfuSystem$10.42+1.6%$7.70$4.61▼$11.04$212.84M1.82179,389 shs316,773 shsISRIsoray$0.37$0.19▼$0.45$54.57M1.48290,697 shs145,000 shsNSPRInspireMD$2.46+2.5%$2.43$1.99▼$3.80$102.63M0.68101,203 shs52,707 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell0.00%-4.32%-10.00%-5.08%+415.27%INFUInfuSystem+0.98%-4.82%+16.19%+69.59%+75.68%ISRIsoray0.00%0.00%0.00%0.00%0.00%NSPRInspireMD-0.83%-1.64%-0.83%-1.64%-14.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/AINFUInfuSystem 4.00Strong Buy$12.5019.96% UpsideISRIsoray 0.00N/AN/AN/ANSPRInspireMD 3.00Buy$4.5082.93% UpsideCurrent Analyst Ratings BreakdownLatest ISR, INFU, NSPR, and CTCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.007/21/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K1,546.92N/AN/A$1.07 per share2.27INFUInfuSystem$139.89M1.52$0.81 per share12.79$2.47 per share4.22ISRIsoray$10.80M0.00N/AN/A$0.43 per share0.00NSPRInspireMD$7.07M14.53N/AN/A$1.83 per share1.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AINFUInfuSystem$870K$0.23173.7033.61N/A1.12%2.78%1.41%N/AISRIsoray-$7.27M-$0.07N/AN/AN/A-115.91%-17.12%-16.15%N/ANSPRInspireMD-$19.92M-$0.83N/AN/AN/A-413.96%-69.42%-57.68%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/AISRIsorayN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29INFUInfuSystem0.501.981.59ISRIsorayN/A14.3813.99NSPRInspireMDN/A6.396.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%INFUInfuSystem71.13%ISRIsoray11.32%NSPRInspireMD44.78%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%INFUInfuSystem11.40%ISRIsoray2.42%NSPRInspireMD34.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableINFUInfuSystem41020.43 million19.10 millionOptionableISRIsorayN/A142.11 million138.67 millionNot OptionableNSPRInspireMD5041.72 million18.33 millionOptionableISR, INFU, NSPR, and CTCX HeadlinesRecent News About These CompaniesParkman Healthcare Partners LLC Acquires 316,700 Shares of InspireMD, Inc. $NSPRSeptember 8 at 7:45 AM | marketbeat.comNantahala Capital Management LLC Has $6.24 Million Stock Position in InspireMD, Inc. $NSPRSeptember 3, 2025 | marketbeat.comFinancial Review: Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) versus InspireMD (NYSE:NSPR)September 1, 2025 | americanbankingnews.comInspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment ConferenceAugust 27, 2025 | globenewswire.comInspireMD Rings the Closing BellAugust 25, 2025 | nasdaq.comInspireMD’s Earnings Call: FDA Approval and Financial ChallengesAugust 15, 2025 | theglobeandmail.comInspireMD, Inc. (NASDAQ:NSPR) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | msn.comInspireMD, Inc. (NSPR) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comInspireMD Reports Second Quarter 2025 Financial ResultsAugust 5, 2025 | globenewswire.comInspireMD Q2 2025 Earnings PreviewAugust 4, 2025 | msn.comWhat to Expect from InspireMD Inc (NSPR) Q2 2025 EarningsAugust 4, 2025 | finance.yahoo.comInvestors in InspireMD (NASDAQ:NSPR) from five years ago are still down 60%, even after 11% gain this past weekAugust 3, 2025 | finance.yahoo.comMarvin Slosman Acquires 10,330 Shares of InspireMD, Inc. (NYSE:NSPR) StockAugust 2, 2025 | insidertrades.comInspireMD brings in $58M, adds former Axonics CEO to boardJuly 31, 2025 | massdevice.comInspireMD Announces the Appointment of Raymond W. Cohen to its Board of DirectorsJuly 31, 2025 | globenewswire.comInspireMD Announces Combined Financings of $58 MillionJuly 31, 2025 | globenewswire.comInspireMD to Announce Second Quarter 2025 Financial ResultsJuly 22, 2025 | globenewswire.comInspireMD Launches CGuard Prime Carotid Stent System in the U.S.July 11, 2025 | zacks.comInspireMD’s CGuard Prime Carotid Stent System Launched in United StatesJuly 10, 2025 | evtoday.comEInspireMD stock rises after US commercial launch of carotid stent systemJuly 10, 2025 | au.investing.comInspireMD launches carotid stent in U.S. after FDA approvalJuly 10, 2025 | massdevice.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Small Cap, Big Potential: 3 Tech Disruptors You Should Know AboutBy Nathan Reiff | August 22, 2025From Debt to Liftoff: EchoStar's $23 Billion CatalystBy Jeffrey Neal Johnson | August 27, 2025ISR, INFU, NSPR, and CTCX Company DescriptionsCarmell NASDAQ:CTCX$2.43 -0.12 (-4.71%) As of 09/5/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.InfuSystem NYSE:INFU$10.42 +0.16 (+1.56%) Closing price 04:00 PM EasternExtended Trading$10.41 -0.01 (-0.06%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Isoray NYSE:ISRIsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.InspireMD NYSE:NSPR$2.46 +0.06 (+2.50%) Closing price 04:00 PM EasternExtended Trading$2.46 0.00 (-0.04%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
